A functional corona around extracellular vesicles enhances angiogenesis, skin regeneration and immunomodulation.

EV corona EV function angiogenesis extracelular vesicle placenta derived stromal cells tangential flow filtration

Journal

Journal of extracellular vesicles
ISSN: 2001-3078
Titre abrégé: J Extracell Vesicles
Pays: United States
ID NLM: 101610479

Informations de publication

Date de publication:
04 2022
Historique:
revised: 08 02 2022
received: 01 10 2021
accepted: 02 03 2022
entrez: 10 4 2022
pubmed: 11 4 2022
medline: 13 4 2022
Statut: ppublish

Résumé

Nanoparticles can acquire a plasma protein corona defining their biological identity. Corona functions were previously considered for cell-derived extracellular vesicles (EVs). Here we demonstrate that nano-sized EVs from therapy-grade human placental-expanded (PLX) stromal cells are surrounded by an imageable and functional protein corona when enriched with permissive technology. Scalable EV separation from cell-secreted soluble factors via tangential flow-filtration (TFF) and subtractive tandem mass-tag (TMT) proteomics revealed significant enrichment of predominantly immunomodulatory and proangiogenic proteins. Western blot, calcein-based flow cytometry, super-resolution and electron microscopy verified EV identity. PLX-EVs partly protected corona proteins from protease digestion. EVs significantly ameliorated human skin regeneration and angiogenesis in vivo, induced differential signalling in immune cells, and dose-dependently inhibited T cell proliferation in vitro. Corona removal by size-exclusion or ultracentrifugation abrogated angiogenesis. Re-establishing an artificial corona by cloaking EVs with fluorescent albumin as a model protein or defined proangiogenic factors was depicted by super-resolution microscopy, electron microscopy and zeta-potential shift, and served as a proof-of-concept. Understanding EV corona formation will improve rational EV-inspired nano-therapy design.

Identifiants

pubmed: 35398993
doi: 10.1002/jev2.12207
pmc: PMC8994701
doi:

Substances chimiques

Protein Corona 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12207

Subventions

Organisme : Land Salzburg
ID : 20102-F2100572-FPREV-Quant
Organisme : Land Salzburg
ID : IWB/EFRE P1812596
Organisme : Land Salzburg
ID : WISS 2025 20102-F1900731-KZP EV-TT
Organisme : Land Salzburg
ID : F2000237-FIPSTEBS
Organisme : Austrian Science Fund
ID : W1213
Organisme : European Commission
ID : 731377
Organisme : European Commission
ID : 733006
Organisme : F 2000237-FIP "STEBS"

Informations de copyright

© 2022 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles.

Références

Biomedicines. 2022 Jan 23;10(2):
pubmed: 35203448
Transfusion. 2007 Aug;47(8):1426-35
pubmed: 17655587
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:125-154
pubmed: 27814025
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Stem Cell Res Ther. 2015 Dec 01;6:236
pubmed: 26620155
J Extracell Vesicles. 2019 Mar 21;8(1):1587567
pubmed: 30949308
Biomacromolecules. 2015 Apr 13;16(4):1311-21
pubmed: 25794196
Small. 2017 Nov;13(41):
pubmed: 28922574
Transfusion. 2007 Aug;47(8):1436-46
pubmed: 17655588
Nat Nanotechnol. 2013 Oct;8(10):772-81
pubmed: 24056901
Biomaterials. 2016 Jan;76:371-87
pubmed: 26561934
Sci Rep. 2020 Mar 24;10(1):5278
pubmed: 32210326
J Extracell Vesicles. 2019 Apr 29;8(1):1609206
pubmed: 31069028
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14265-70
pubmed: 18809927
Nat Nanotechnol. 2021 Mar;16(3):229-242
pubmed: 33597736
J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1079-1092
pubmed: 30334381
Lancet Glob Health. 2019 Aug;7(8):e1020-e1030
pubmed: 31303293
J Transl Med. 2015 Nov 10;13:354
pubmed: 26554451
J Extracell Vesicles. 2015 Dec 31;4:30087
pubmed: 26725829
Nanoscale. 2017 Jun 29;9(25):8858-8870
pubmed: 28632260
Theranostics. 2021 Jul 25;11(17):8430-8447
pubmed: 34373751
Exp Cell Res. 2018 Apr 1;365(1):78-84
pubmed: 29476835
Nucleic Acids Res. 2017 Jan 4;45(D1):D158-D169
pubmed: 27899622
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
J Extracell Vesicles. 2013 Sep 12;2:
pubmed: 24223256
Cell Mol Life Sci. 2019 Jun;76(12):2369-2382
pubmed: 30891621
Int J Mol Sci. 2017 Jul 01;18(7):
pubmed: 28671586
Nat Biotechnol. 2014 Mar;32(3):252-60
pubmed: 24561556
Blood. 2009 Jun 25;113(26):6716-25
pubmed: 19321860
J Vis Exp. 2009 Oct 08;(32):
pubmed: 19816400
Cytotherapy. 2017 Dec;19(12):1438-1446
pubmed: 29122516
J Invest Dermatol. 2000 Apr;114(4):674-80
pubmed: 10733672
Front Immunol. 2018 Jun 13;9:1326
pubmed: 29951064
J Struct Biol. 2005 Oct;152(1):36-51
pubmed: 16182563
J Extracell Vesicles. 2016 Feb 19;5:29975
pubmed: 26901056
J Extracell Vesicles. 2015 May 14;4:27066
pubmed: 25979354
Nat Nanotechnol. 2021 Jul;16(7):748-759
pubmed: 34211166
J Vis Exp. 2009 Oct 30;(32):
pubmed: 19881465
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
J Extracell Vesicles. 2014 Sep 30;3:
pubmed: 25317276
J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):880-897
pubmed: 30230266
Eur J Vasc Endovasc Surg. 2019 Apr;57(4):538-545
pubmed: 30686676
Bioconjug Chem. 2019 Mar 20;30(3):920-930
pubmed: 30768246
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
J Extracell Vesicles. 2021 Sep;10(11):e12140
pubmed: 34520123
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2050-5
pubmed: 17267609
J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):501-516
pubmed: 30843380

Auteurs

Martin Wolf (M)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

Rodolphe W Poupardin (RW)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

Patricia Ebner-Peking (P)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

André Cronemberger Andrade (AC)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

Constantin Blöchl (C)

Department of Biosciences, Paris Lodron University Salzburg, Salzburg, Austria.

Astrid Obermayer (A)

Department of Biosciences, Paris Lodron University Salzburg, Salzburg, Austria.

Fausto Gueths Gomes (FG)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.
Department of Transfusion Medicine and SCI-TReCS, PMU, Salzburg, Austria.

Balazs Vari (B)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

Nicole Maeding (N)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

Essi Eminger (E)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

Heide-Marie Binder (HM)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

Anna M Raninger (AM)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

Sarah Hochmann (S)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

Gabriele Brachtl (G)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

Andreas Spittler (A)

Core Facility Flow Cytometry and Department of Surgery, Research Laboratories, Medical University of Vienna, Vienna, Austria.

Thomas Heuser (T)

Vienna Biocentre Core Facilities, Vienna, Austria.

Racheli Ofir (R)

Pluristem Ltd., Haifa, Israel.

Christian G Huber (CG)

Department of Biosciences, Paris Lodron University Salzburg, Salzburg, Austria.

Zami Aberman (Z)

Pluristem Ltd., Haifa, Israel.

Katharina Schallmoser (K)

Department of Transfusion Medicine and SCI-TReCS, PMU, Salzburg, Austria.

Hans-Dieter Volk (HD)

Berlin Institute of Health at Charité - Universitätsmedizin, BIH Centre for Regenerative Therapies (BCRT), Berlin, Germany.

Dirk Strunk (D)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH